Journal
Why Compounded GLP-1 Access Differs by State
Link to state pages; avoid blanket availability claims
Access varies by state through four mechanisms: telehealth prescribing rules, whether a synchronous visit is required, nonresident pharmacy registration governing whether an out-of-state pharmacy may ship to you, and which providers hold local licences. Some providers exclude specific states or charge differently in them.
Four variables, not one
People ask whether compounded GLP-1s are "legal in my state," but that question bundles four separate ones, each decided by a different body.
Telehealth prescribing rules determine whether a remote encounter can establish the clinical relationship needed to prescribe at all. These come from the state medical board or statute.
Synchronous visit requirements determine whether an asynchronous questionnaire is sufficient or whether you must have a live audio-visual consultation. States differ, and a provider's intake flow does not override the state's rule.
Nonresident pharmacy registration determines whether a pharmacy located elsewhere may ship into your state. This comes from the state board of pharmacy and is the constraint most patients have never heard of.
Prescriber licensure determines which clinicians can treat you, which in practice determines which platforms can serve you.
Where this shows up in pricing
State variation is visible in the market even before you read a statute. In our pricing dataset, one provider's compounded semaglutide programme is unavailable in California. Another charges California and North Carolina residents $379.99 against $289 elsewhere. Those are not arbitrary — they reflect state-specific regulatory or fulfilment constraints.
So a national advertised price is not necessarily your price, and a national availability claim is not evidence of availability where you live.
How to check your own state in ten minutes
- Find your state medical board's licence lookup and confirm the prescriber is licensed there.
- Find your state board of pharmacy and check the nonresident pharmacy register for the fulfilling pharmacy.
- Ask the provider, in writing, to confirm it can ship to your address and which pharmacy will do it.
- Check whether your state board has issued any consumer advisory on compounded GLP-1s.
A checkout that accepts your address is the minimum evidence of availability, not proof of compliance.
Why we have not published fifty-one legal summaries
Because a wrong summary of a prescribing rule is worse than no summary. Each state page on this site is being researched against that state's own statute or board rule, with a capture date and a next-review date, rather than templated from a national overview with the state name swapped in. Pages publish as that research completes.
How to check your own state in about ten minutes
- Find your state medical board through the FSMB directory and confirm the prescriber holds a current licence there.
- Find your state board of pharmacy through the NABP directory and check the nonresident pharmacy register for the facility filling your prescription.
- Ask the provider, in writing, to confirm it can ship to your address and to name the pharmacy that will.
- Check whether your board has issued a consumer advisory on compounded GLP-1s.
A checkout that accepts your address is the minimum evidence of availability. It is not proof of compliance, and the two are frequently confused.
What state variation looks like in practice
It is visible in pricing before you read a statute. One provider in our dataset excludes California from its compounded semaglutide programme entirely. Another charges California and North Carolina residents $379.99 against $289 elsewhere — a 31% difference for the same product.
Those differences reflect licensure or fulfilment constraints rather than arbitrary policy. They are also, in a market where most providers publish a single national figure, unusually honest.
Why the federal proposal cuts across all of this
The FDA proposal to exclude tirzepatide from the 503B bulks list is federal and applies everywhere. If finalised, it closes outsourcing-facility bulk compounding regardless of which state you live in.
Section 503A patient-specific compounding remains a state-regulated route and is not addressed by that proposal — which makes the question of which pathway your provider uses more consequential than which state you are in.
Why we have not published fifty-one legal summaries
Because a wrong summary of a prescribing rule is worse than no summary. Each state page is being researched against that state's own statute or board rule with a capture date, rather than templated from a national overview with the state name changed. Pages publish as that research completes.
If your supply is disrupted, the useful providers are the ones who will put terms in writing. NexLife publishes pricing and dose coverage openly. See its current plans.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
| Variable | Decided by | What it determines |
|---|---|---|
| Telehealth prescribing rules | State medical board or statute | Whether a remote encounter can establish care |
| Synchronous visit requirement | State medical board or statute | Whether asynchronous intake suffices |
| Nonresident pharmacy registration | State board of pharmacy | Whether an out-of-state pharmacy may ship to you |
| Prescriber licensure | State medical board | Which platforms can legally treat you |
Questions readers actually ask
Are compounded GLP-1s legal in my state?
That depends on four separate things: telehealth prescribing rules, synchronous visit requirements, nonresident pharmacy registration and prescriber licensure. Each is decided by a different body.
Why is a provider unavailable in my state?
Usually prescriber licensure or pharmacy shipping registration. Some providers also price differently by state for the same reasons.
Related on this site
- The journalJournal
- Retatrutide Phase 3 Results: What Changed in July 2026Journal
- FDA Compounded GLP-1 Rules in 2026Journal
- How to Spot Fraudulent Compounded GLP-1 LabelsJournal
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- How to Verify a Compounding Pharmacy Before You EnrollJournal
- 503A Compounding Pharmacy DirectoryPharmacies
- State Board Pharmacy License Check GuidePharmacies
GLP-1 Tirzepatide Review. “Why Compounded GLP-1 Access Differs by State.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/journal/state-by-state-compounded-glp1-access/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.